Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kyowa Hakko Kirin
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for KK-2845](https://pryzm-maps.s3.us-west-2.amazonaws.com/7current_maps.png)
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2011240008 | P1 |
Not yet recruiting |
Acute Myeloid Leukemia |
2028-04-30 |